#1 Clinical Trials Search in Europe

Rilvegostomig

Rilvegostomig is an innovative bispecific antibody being investigated in multiple clinical trials for the treatment of various cancers, particularly non-small cell lung cancer (NSCLC). This article examines the ongoing research into rilvegostomig’s potential as an immunotherapy agent, either alone or in combination with other treatments, to improve outcomes for cancer patients.

Table of Contents

What is Rilvegostomig?

Rilvegostomig, also known as AZD2936, is a new type of cancer drug currently being studied in clinical trials[1]. It belongs to a class of medications called bispecific antibodies, which are designed to target two different proteins in the body at the same time[2]. Specifically, rilvegostomig targets two proteins called TIGIT and PD-1, both of which play important roles in regulating the immune system’s response to cancer cells.

How Does Rilvegostomig Work?

Rilvegostomig works by helping the body’s immune system fight cancer more effectively. It does this by blocking two different “checkpoint” proteins (TIGIT and PD-1) that cancer cells sometimes use to evade detection by the immune system[2]. By targeting both of these proteins at once, rilvegostomig may be able to enhance the immune system’s ability to recognize and attack cancer cells.

What Conditions Does Rilvegostomig Treat?

Rilvegostomig is being studied for the treatment of several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer[1][3]
  • Biliary tract cancer: This includes cancers of the bile ducts and gallbladder[4]
  • Hepatocellular carcinoma: This is the most common type of liver cancer[5]
  • Intrahepatic cholangiocarcinoma: A type of liver cancer that starts in the bile ducts inside the liver[6]

Current Clinical Trials

Rilvegostomig is currently being tested in several large-scale clinical trials, including:

  • ARTEMIDE-Lung03: This study is comparing rilvegostomig to another immunotherapy drug called pembrolizumab in patients with advanced non-squamous non-small cell lung cancer[3]
  • ARTEMIDE-Lung02: Similar to ARTEMIDE-Lung03, but focusing on patients with squamous non-small cell lung cancer[7]
  • ARTEMIDE-Biliary01: This trial is testing rilvegostomig as an additional treatment after surgery for biliary tract cancer[4]
  • TROPION-Lung12: This study is looking at rilvegostomig in combination with another drug called datopotamab deruxtecan for early-stage lung cancer[8]

Potential Benefits of Rilvegostomig

While research is still ongoing, early studies suggest that rilvegostomig may offer several potential benefits:

  • Improved survival: Many trials are looking at whether rilvegostomig can help patients live longer without their cancer getting worse (progression-free survival) or increase overall survival[3]
  • Better tumor response: Researchers are studying if rilvegostomig can shrink tumors more effectively than existing treatments[3]
  • Combination potential: Rilvegostomig is being tested both alone and in combination with other cancer treatments, which may lead to more effective therapies[1]
  • New option for hard-to-treat cancers: Some of the cancers being studied, like biliary tract cancer, currently have limited treatment options[4]

Possible Side Effects

As with all medications, rilvegostomig may cause side effects. While the full safety profile is still being studied, some potential side effects may include:

  • Fatigue
  • Nausea
  • Decreased appetite
  • Immune-related side effects (due to its effects on the immune system)

It’s important to note that the exact side effects and their frequency are still being determined through clinical trials[1].

Future Outlook

Rilvegostomig is still in the experimental stage and is not yet approved for general use. However, the ongoing clinical trials are providing valuable information about its effectiveness and safety. If the results from these studies are positive, rilvegostomig could become an important new option for treating various types of cancer in the future.

Patients interested in learning more about rilvegostomig should speak with their healthcare provider about the latest research and whether participating in a clinical trial might be appropriate for their individual situation.

Aspect Details
Drug Name Rilvegostomig (AZD2936)
Drug Type Bispecific antibody targeting TIGIT and PD-1
Primary Indications Non-small cell lung cancer (NSCLC), Biliary tract cancer, Hepatocellular carcinoma, Gastric cancer
Administration Intravenous (IV) infusion, typically every 3 weeks (Q3W)
Key Clinical Trials ARTEMIDE-Lung02, ARTEMIDE-Lung03, TROPION-Lung10, TROPION-Lung12, DESTINY-Lung03
Combination Therapies Chemotherapy (e.g., platinum-based), Other immunotherapies (e.g., Datopotamab Deruxtecan), Targeted therapies
Primary Endpoints Overall survival (OS), Progression-free survival (PFS), Objective response rate (ORR)
Secondary Endpoints Duration of response (DoR), Disease control rate (DCR), Quality of life measures, Pharmacokinetics, Immunogenicity
Safety Monitoring Adverse events (AEs), Serious adverse events (SAEs), Dose-limiting toxicities (DLTs)
Development Stage Phase II and Phase III clinical trials

FAQ

  • What is rilvegostomig? Rilvegostomig is a novel bispecific antibody that targets both TIGIT and PD-1 proteins. It is designed to enhance the immune system's ability to fight cancer cells.
  • What types of cancer is rilvegostomig being studied for? Rilvegostomig is primarily being investigated for non-small cell lung cancer (NSCLC), but it is also being studied in trials for other cancers such as biliary tract cancer, hepatocellular carcinoma, and gastric cancer.
  • How is rilvegostomig administered? Rilvegostomig is typically administered as an intravenous (IV) infusion, usually given every 3 weeks (Q3W) in clinical trials.
  • What are some potential side effects of rilvegostomig? As with many cancer treatments, rilvegostomig may cause side effects. These are being closely monitored in clinical trials. Common side effects of immunotherapies can include fatigue, skin reactions, and immune-related adverse events.
  • Is rilvegostomig approved for use outside of clinical trials? Currently, rilvegostomig is still in the investigational stage and is not approved for general use outside of clinical trials. Its safety and efficacy are being evaluated in various phase II and III studies.

Ongoing Clinical Trials on Rilvegostomig

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +3

  • A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

  • Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark Finland France Germany +7

  • Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Bulgaria France Germany Greece Ireland +4

  • Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +3

  • Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +4

  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy The Netherlands Poland Spain

  • Study comparing Rilvegostomig plus chemotherapy versus Pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

Glossary

  • Rilvegostomig: A bispecific antibody that targets both TIGIT and PD-1 proteins, designed to enhance the immune system's response against cancer cells.
  • NSCLC: Non-small cell lung cancer, a type of lung cancer that is the focus of many rilvegostomig clinical trials.
  • Bispecific antibody: An engineered protein that can simultaneously bind to two different types of antigens or targets.
  • PD-1: Programmed cell death protein 1, a protein found on immune cells that some cancer cells can exploit to evade the immune system.
  • TIGIT: T cell immunoreceptor with Ig and ITIM domains, an immune checkpoint protein that can inhibit T cell activation.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Clinical trial: A research study that tests how well new medical approaches work in people.
  • Intravenous (IV) infusion: A method of delivering medications directly into a vein using a needle or catheter.
  • Q3W: Every 3 weeks, referring to the frequency of treatment administration.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Antidrug antibodies (ADAs): Antibodies produced by the immune system against a therapeutic drug, which can affect its efficacy and safety.

References